Secretropin
Secretropin is the first clinically proven natural stimulator of growth hormone production, and is gaining the medical community's acceptance as a more desirable "first step" approach to pursuing hormonal balance.

Developed in 2001, the product virtually sat on the shelf due to the availability of recombinant human growth hormone (rhGH). Between 2001 and 2006, the product was sold quietly to patients that preferred not to pay the high price of rhGH. Secretropin received early medical acknowledgment for its reproducible effectiveness and its preferable oral delivery. In as little as 4 weeks Secretropin has been shown to increase the production of human growth hormone by 50 - 200% while being delivered as an oral spray. Secretropin's oral delivery system owes its effectiveness to the latest nanoliposomal technology, which wraps the active agents in a protective envelope. Until this delivery technology was available, stomach acid would inactivate and destroy the active agents responsible for the increase in growth hormone production.

Prior to Secretropin, the injectable growth hormone was the only viable option for increasing human growth hormone. Fortunately, the nanoliposomal technology protects the complex, allowing for optimal absorption and leading to a more natural increase in growth hormone levels—thus eliminating the less desirable approach of daily injections.

In October 2006, an initial study group of 50 individuals was employed for a prospective, 12-month study on the product's efficacy on increasing IGF-1 and IGFBP-3 levels. As this study approached completion in January 2008, a subsequent study design was begun to include multiple centers for a continued long term assessment of the product's efficacy. We anticipate employing hundreds of new patients. It is the goal of these studies to constantly show the efficacy and related benefits from an amino acid complex growth hormone stimulator.

Download the entire study >>

Contact Dr. Bronner about Secretropin Anti-Aging Therapy


Secretropin Proprietary Blend
Active Ingredients: Pyroglutamine,L-Glutamine, L-Arginine, L-Lysine, L-Valine,L-Tyrosine Alpha-ketoglutarate, L-Ornithine, L-alphaglycerlphosphoryl-choline, Gamma Amino Butyric Acid(GABA), and Mucina pruriens.

Other Ingredients: Deionized water, Lecithin, Phospholipids, Sodium citrate, Citric acid, Maltodextrin, Potassium sorbate, Artificial color and Flavor.

Secretropin Instructions
Morning, upon arising, pump 2 sprays under the tongue and hold for 30 seconds before swallowing. Perform this process 30 minutes before a meal and then wait 30 minutes before eating or drinking. If you eat, then wait 30 minutes before using.

Evening, before bed, place 4 sprays under the tongue and hold for 30 seconds before swallowing. Perform this process 30 minutes before a meal and then wait 30 minutes before eating or drinking. If you eat, then wait 30 minutes before using.

Note: Individuals larger than 250 pounds may need to increase the morning dose from two(2) pumps to four(4) pumps.

Warnings
This product is not intended for use by anyone under the age of 18 years. This product should not be used if you are pregnant or nursing. Keep this product out of reach of children. Do not use if seal is broken.  In the event of any adverse reaction immediately discontinue use and consult your physician.

Patient Monitoring
Secretropin works within the body’s regulatory mechanisms to increase the amount of growth hormone that is produced and released by the anterior pituitary gland. In response to an increase in the production and release of growth hormone, the body’s natural tendency is to decrease the level. Normally, there is an up and down production of growth hormone throughout the night and early morning. Your doctor will run blood tests that can still show that there had been an increase in the production of growth hormone and IGF-1.

To learn about the relationship between Growth Hormone, Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3; Click Here >>


GH, IGF-1, and IGFBP-3; The Relationship

Growth Hormone: The half-life of human growth hormone in serum is about 20 minutes, making it an unreliable hormone to measure on a random basis since its measurement represents merely a snapshot of the blood.

Urine Growth Hormone: Either by 24 hour or first morning urine testing, the level of human growth hormone can be accurately measured. This mode of testing in conjunction with IGF-1 and IGFBP-3 is gaining ground as a reproducible means of diagnosing Adult Growth Hormone Deficiency.

Insulin-like Growth Factor-1: The half-life of IGF-1 has for many years been accepted as being 20 hours, while in fact, it is only 8 minutes. The extended half-life is based upon its prolonged survival in the blood when attached to the carrier protein IGFBP-3. Therefore, like measurement of GH, IGF-1's short half-life make its random testing unreliable.

IGF Binding Protein-3: This protein is responsible for binding to IGF-1 thereby extending its half-life from 8 minutes to 20 hours. Free or unbound BP-3 has a half-life of 20 hours. This makes BP-3 an ideal inferential marker for growth hormone since (so far) only GH, Estradiol and Quercitin increase the production of IGFBP-3 from the liver.

Initial Testing
Results
IGF-1
Less than 150ng/ml
IGFBP-3
Less than 3000ng/ml
Urine Growth Hormone
Less than 500 ug/g Creatine 
DHEA-s
Median for gender at 25 y/o
Free Testosterone
Median for gender at 25 y/o
Dihydrotestosterone
Median for gender at 25 y/o
Estradiol (E2)
Median for gender at 25 y/o
Pregnenolone
Median for gender at 25 y/o

Follow-up Testing
Results
IGF-1
Less than 150ng/ml
IGFBP-3
Less than 3000ng/ml
Urine Growth Hormone
Less than 500 ug/g Creatine 

Ideally, all three of these tests need to be low in order to support a diagnosis of Adult Growth Hormone Deficiency. Due to Secretropin's ability to increase GH/IGF-1 and BP-3, we recommend an initial three month trial in any patient that is non-medically challenged before deciding on injectable Growth Hormone. As always, the final decision will be between the doctor and the patient.